235 related articles for article (PubMed ID: 30832253)
1. Quantitative Measurement of Functional Activity of the PI3K Signaling Pathway in Cancer.
van de Stolpe A
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30832253
[TBL] [Abstract][Full Text] [Related]
2. Enabling precision medicine by unravelling disease pathophysiology: quantifying signal transduction pathway activity across cell and tissue types.
van de Stolpe A; Holtzer L; van Ooijen H; Inda MA; Verhaegh W
Sci Rep; 2019 Feb; 9(1):1603. PubMed ID: 30733525
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Immunoactive and Immunotolerant CD4+ T Cells in Breast Cancer by Measuring Activity of Signaling Pathways That Determine Immune Cell Function.
Wesseling-Rozendaal Y; van Doorn A; Willard-Gallo K; van de Stolpe A
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158758
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Functional Phosphatidylinositol 3-Kinase Pathway Activity in Cancer Tissue Using Forkhead Box-O Target Gene Expression in a Knowledge-Based Computational Model.
van Ooijen H; Hornsveld M; Dam-de Veen C; Velter R; Dou M; Verhaegh W; Burgering B; van de Stolpe A
Am J Pathol; 2018 Sep; 188(9):1956-1972. PubMed ID: 30030980
[TBL] [Abstract][Full Text] [Related]
5. ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen.
Sieuwerts AM; Inda MA; Smid M; van Ooijen H; van de Stolpe A; Martens JWM; Verhaegh WFJ
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32230714
[No Abstract] [Full Text] [Related]
6. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
7. FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway.
Lin A; Piao HL; Zhuang L; Sarbassov dos D; Ma L; Gan B
Cancer Res; 2014 Mar; 74(6):1682-93. PubMed ID: 24448243
[TBL] [Abstract][Full Text] [Related]
8. Androgen Receptor Pathway Activity Assay for Sepsis Diagnosis and Prediction of Favorable Prognosis.
Bouwman W; Verhaegh W; van de Stolpe A
Front Med (Lausanne); 2021; 8():767145. PubMed ID: 34888328
[No Abstract] [Full Text] [Related]
9. Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer.
Yu L; Wei J; Liu P
Semin Cancer Biol; 2022 Oct; 85():69-94. PubMed ID: 34175443
[TBL] [Abstract][Full Text] [Related]
10. Improved diagnosis of inflammatory bowel disease and prediction and monitoring of response to anti-TNF alpha treatment based on measurement of signal transduction pathway activity.
Bouwman W; Verhaegh W; van de Stolpe A
Front Pharmacol; 2022; 13():1008976. PubMed ID: 37090899
[No Abstract] [Full Text] [Related]
11. Molecular mechanisms underlying the action of carcinogens in gastric cancer with a glimpse into targeted therapy.
Patrad E; Khalighfard S; Amiriani T; Khori V; Alizadeh AM
Cell Oncol (Dordr); 2022 Dec; 45(6):1073-1117. PubMed ID: 36149600
[TBL] [Abstract][Full Text] [Related]
12. Regulatory effects of antitumor agent matrine on FOXO and PI3K-AKT pathway in castration-resistant prostate cancer cells.
Li Q; Huang H; He Z; Sun Y; Tang Y; Shang X; Wang C
Sci China Life Sci; 2018 May; 61(5):550-558. PubMed ID: 29119376
[TBL] [Abstract][Full Text] [Related]
13. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
Burris HA
Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372
[TBL] [Abstract][Full Text] [Related]
14. Multipoint targeting of the PI3K/mTOR pathway in mesothelioma.
Zhou S; Liu L; Li H; Eilers G; Kuang Y; Shi S; Yan Z; Li X; Corson JM; Meng F; Zhou H; Sheng Q; Fletcher JA; Ou WB
Br J Cancer; 2014 May; 110(10):2479-88. PubMed ID: 24762959
[TBL] [Abstract][Full Text] [Related]
15. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
16. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
17. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
[TBL] [Abstract][Full Text] [Related]
18. Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment.
Raith F; O'Donovan DH; Lemos C; Politz O; Haendler B
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768610
[TBL] [Abstract][Full Text] [Related]
19. Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review.
Singh P; Kumar V; Gupta SK; Kumari G; Verma M
Med Oncol; 2021 Jan; 38(1):10. PubMed ID: 33452624
[TBL] [Abstract][Full Text] [Related]
20. Alterations in the RTK/Ras/PI3K/AKT pathway serve as potential biomarkers for immunotherapy outcome of diffuse gliomas.
Han S; Wang PF; Cai HQ; Wan JH; Li SW; Lin ZH; Yu CJ; Yan CX
Aging (Albany NY); 2021 Jun; 13(11):15444-15458. PubMed ID: 34100771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
